GSK
GSK plc · Healthcare · Drug Manufacturers - General
Momentum inputs (comparable managers):
holder breadth +25.0% ·
share flow +2.0% ·
net new positions +20.0%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 118 | +2 | 291.90M | $15.17B | +8 | −5 |
| Q1 2026 | 116 | 0 | 315.42M | $17.28B | +8 | −8 |
| Q4 2025 | 115 | +4 | 328.16M | $15.98B | +4 | — |
| Q3 2025 | 18 | -1 | 242.57M | $10.47B | +1 | −3 |
| Q2 2025 | 17 | +1 | 220.73M | $8.48B | +2 | −1 |
| Q1 2025 | 14 | -1 | 157.56M | $6.11B | — | −1 |
| Q4 2024 | 15 | -1 | 135.53M | $4.59B | — | −1 |
| Q3 2024 | 15 | +3 | 120.78M | $4.99B | +3 | — |
| Q2 2024 | 12 | — | 118.47M | $4.56B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Dodge & Cox ✦ | 68.09M | -0.4% | $2.78B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 2 | Fisher Asset Management ✦ | 18.58M | +4.9% | $759.42M | 0.3% | ▲ Add | 2 | SEC ↗ |
| 3 | PRIMECAP Management ✦ | 14.85M | +2.4% | $607.22M | 0.4% | ▲ Add | 2 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 7.53M | -26.4% | $307.90M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 7.53M | -26.4% | $307.90M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 6 | Arrowstreet Capital ✦ | 3.87M | +50.0% | $211.55M | 0.2% | ▲ Add | 2 | SEC ↗ |
| 7 | Renaissance Technologies ✦ | 2.34M | -0.5% | $95.47M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 8 | Wellington Management ✦ | 1.90M | -7.8% | $77.84M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 9 | Wellington Management ✦ | 1.90M | -7.8% | $77.84M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 10 | Wellington Management ✦ | 1.90M | -7.8% | $77.84M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 11 | Wellington Management ✦ | 1.90M | -7.8% | $77.84M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 12 | Wellington Management ✦ | 1.90M | -7.8% | $77.84M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 13 | Wellington Management ✦ | 1.90M | -7.8% | $77.84M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 14 | Millennium Management ✦ | 1.46M | +1849.1% | $59.64M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 15 | Bridgewater Associates ✦ | 965.84K | +107.3% | $39.48M | 0.2% | ▲ Add | 2 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 577.04K | +4072.7% | $23.59M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 17 | Citadel Advisors ✦ | 577.04K | +4072.7% | $23.59M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 18 | Marshall Wace ✦ | 283.38K | New | $11.58M | 0.0% | New | 1 | SEC ↗ |
| 19 | D. E. Shaw & Co. ✦ | 122.86K | New | $5.02M | 0.0% | New | 1 | SEC ↗ |
| 20 | Tweedy, Browne ✦ | 108.03K | -1.7% | $4.42M | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 21 | Two Sigma Investments ✦ | 81.82K | New | $3.34M | 0.0% | New | 1 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 27.45K | +4.1% | $1.12M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 23 | AQR Capital Management ✦ | 27.45K | +4.1% | $1.12M | 0.0% | ▲ Add | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $11.58M | 0.0% |
| D. E. Shaw & Co. | $5.02M | 0.0% |
| Two Sigma Investments | $3.34M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 2 holders, 16.10M shares, $459.30M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.